FAPI PET/CT Imaging-An Updated Review.

ABSTRACT: Despite revolutionizing the field of oncological imaging, Positron Emission Tomography (PET) with [¹⁸F]Fluorodeoxyglucose (FDG) as its workhorse is limited by a lack of specificity and low sensitivity in certain tumor subtypes. Fibroblast activation protein (FAP), a type II transmembrane glycoprotein, is expressed by cancer-associated fibroblasts (CAFs) that form a major component of the tumor stroma. FAP holds the promise to be a pan-cancer target, owing to its selective over-expression in a vast majority of neoplasms, particularly epithelial cancers. Several radiolabeled FAP inhibitors (FAPI) have been developed for molecular imaging and potential theranostic applications. Preliminary data on FAPI PET/CT remains encouraging, with extensive multi-disciplinary clinical research

SUBMITTER: Chandekar KR 

PROVIDER: S-EPMC10297281 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature